Anifrolumab-fnia, an IFNAR1-blocking monoclonal antibody, is now authorized for weekly subcutaneous self-administration in ...
AstraZeneca’s SAPHNELO ® (anifrolumab-fnia) has been approved in the US for self-administration as a once-weekly autoinjector ...
AstraZeneca's Saphnelo (anifrolumab) has been approved in the US for self-administration as a once-weekly autoinjector, the Saphnelo Pen, for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results